Medafor Signs Distribution Agreement with Abbott Animal Health, a Division of Abbott Laboratories
Abbott to Sell Medafor's HemaBlock™ Worldwide

Minneapolis, Minn., June 10, 2002 — Medafor, Inc., a market innovator in the development of advanced hemostasis and wound management technology, announced today that it has signed an exclusive, multi-year agreement with Abbott Laboratories for the distribution of HemaBlock™ “Stop the Bleed” to the veterinary market in the United States and worldwide.

HemaBlock™, is a microporous, polysaccharide powder hemostat based on Medafor’s patented microsphere technology. HemaBlock™ will be marketed to veterinarians for surgical, dental and critical care applications, providing a breakthrough hemostatic alternative which may result in faster procedural completion times and less discomfort for the patient animal versus current methods of hemostasis.

“We are delighted to offer veterinarians an easy-to-use product that stops bleeding fast, causing less blood loss to the animal,” said Diane Winnard, general manager, Abbott Animal Health. “Providing this product to the companion animal market is one more step Abbott Animal Health is taking to be a trusted advisor for the veterinary community.”

Robert Cerza, Executive V.P. for Business Development at Medafor, Inc., said, “In Abbott Animal Health, Medafor has a world-class partner who is committed to bringing innovative healthcare solutions to underserved clinical needs. HemaBlock™ represents a major advancement in hemostatic technology which is already receiving high marks from industry leaders. We anticipate HemaBlock™ will quickly become a routine and essential tool for the veterinarian within the surgical and treatment environment.”

Medafor, Inc., is a privately held Minnesota corporation, founded in 1999 to develop and market its unique, patented hemostatic technology based on engineered biopolymeric microporous particles. For information visit www.medafor.com.

Abbott Laboratories is a global, broad-based healthcare company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals and medical products, including devices and diagnostics. The company employs approximately 70,000 people and markets its products in more than 130 countries. Abbott’s news releases and other information are available on the company’s web site at www.abbott.com.

This release may contain forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unforeseen risks or circumstances materialize, actual results could vary materially from expectations and projections stated herein. The company assumes no obligation to update any forward-looking statements as a result of new information or future developments. BACK.